Search Results - "Narunsky, Kim"

Phase II Dose-Ranging Trial of the Early Bactericidal Activity of PA-824 by Diacon, Andreas H, Dawson, Rodney, du Bois, Jeannine, Narunsky, Kim, Venter, Amour, Donald, Peter R, van Niekerk, Christo, Erondu, Ngozi, Ginsberg, Ann M, Becker, Piet, Spigelman, Melvin K

“…PA-824 is a novel nitroimidazo-oxazine under evaluation as an antituberculosis agent. A dose-ranging randomized study was conducted to evaluate the safety,…”
Get full text

Early Bactericidal Activity and Pharmacokinetics of PA-824 in Smear-Positive Tuberculosis Patients by DIACON, Andreas H, DAWSON, Rodney, LAURENZI, Martino W, GINSBERG, Ann M, SPIGELMAN, Melvin K, HANEKOM, Madeleine, NARUNSKY, Kim, MARITZ, Stefan J, VENTER, Amour, DONALD, Peter R, VAN NIEKERK, Christo, WHITNEY, Karl, ROUSE, Doris J

“…Classifications Services AAC Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit…”
Get full text

Drug susceptibility patterns of Mycobacterium tuberculosis from adults with multidrug-resistant tuberculosis and implications for a household contact preventive therapy trial by Demers, Anne-Marie, Kim, Soyeon, McCallum, Sara, Eisenach, Kathleen, Hughes, Michael, Naini, Linda, Mendoza-Ticona, Alberto, Pradhan, Neeta, Narunsky, Kim, Poongulali, Selvamuthu, Badal-Faesen, Sharlaa, Upton, Caryn, Smith, Elizabeth, Shah, N Sarita, Churchyard, Gavin, Gupta, Amita, Hesseling, Anneke, Swindells, Susan

“…Drug susceptibility testing (DST) patterns of Mycobacterium tuberculosis (MTB) from patients with rifampicin-resistant tuberculosis (RR-TB) or…”
Get full text

A dose-ranging trial to optimize the dose of rifampin in the treatment of tuberculosis by Boeree, Martin J, Diacon, Andreas H, Dawson, Rodney, Narunsky, Kim, du Bois, Jeannine, Venter, Amour, Phillips, Patrick P J, Gillespie, Stephen H, McHugh, Timothy D, Hoelscher, Michael, Heinrich, Norbert, Rehal, Sunita, van Soolingen, Dick, van Ingen, Jakko, Magis-Escurra, Cecile, Burger, David, Plemper van Balen, Georgette, Aarnoutse, Rob E

“…Rifampin at a dose of 10 mg/kg was introduced in 1971 based on pharmacokinetic, toxicity, and cost considerations. Available data in mice and humans showed…”
Get full text

High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial by Boeree, Martin J, PhD, Heinrich, Norbert, MD, Aarnoutse, Rob, PhD, Diacon, Andreas H, PhD, Dawson, Rodney, PhD, Rehal, Sunita, MSc, Kibiki, Gibson S, Prof, Churchyard, Gavin, Prof, Sanne, Ian, FRCP, Ntinginya, Nyanda E, MD, Minja, Lilian T, MD, Hunt, Robert D, BSc, Charalambous, Salome, PhD, Hanekom, Madeleine, PhD, Semvua, Hadija H, PhD, Mpagama, Stellah G, PhD, Manyama, Christina, MD, Mtafya, Bariki, MSc, Reither, Klaus, MD, Wallis, Robert S, Prof, Venter, Amour, NatDipMicr, Narunsky, Kim, MD, Mekota, Anka, PhD, Henne, Sonja, MSc, Colbers, Angela, PhD, van Balen, Georgette Plemper, PhD, Gillespie, Stephen H, Prof, Phillips, Patrick P J, PhD, Hoelscher, Michael, Prof

“…Summary Background Tuberculosis is the world's leading infectious disease killer. We aimed to identify shorter, safer drug regimens for the treatment of…”
Get full text

Increased bactericidal activity but dose-limiting intolerability at 50 mg.kg(-1) rifampicin by te Brake, Lindsey H. M., de Jager, Veronique, Narunsky, Kim, Vanker, Naadira, Svensson, Elin, Phillips, Patrick P. J., Gillespie, Stephen H., Heinrich, Norbert, Hoelscher, Michael, Dawson, Rodney, Diacon, Andreas H., Aamoutse, Rob E., Boeree, Martin J.

“…Accumulating data have indicated that higher rifampicin doses are more effective and shorten tuberculosis treatment duration. This study evaluated the safety,…”
Get full text

Assessing Pretomanid for Tuberculosis (APT), a Randomized Phase 2 Trial of Pretomanid-Containing Regimens for Drug-Sensitive Tuberculosis: 12-Week Results by Dooley, Kelly E, Hendricks, Bronwyn, Gupte, Nikhil, Barnes, Grace, Narunsky, Kim, Whitelaw, Colleen, Smit, Tanya, Ignatius, Elisa H, Friedman, Adine, Dorman, Susan E, Dawson, Rodney

“…Pretomanid is a new nitroimidazole with proven treatment-shortening efficacy in drug-resistant tuberculosis. Pretomanid-rifamycin-pyrazinamide combinations are…”
Get full text

Phase I Single Ascending Dose and Food Effect Study in Healthy Adults and Phase I/IIa Multiple Ascending Dose Study in Patients with Pulmonary Tuberculosis to Assess Pharmacokinetics, Bactericidal Activity, Tolerability, and Safety of OPC-167832 by Dawson, Rodney, Diacon, Andreas H, Narunsky, Kim, De Jager, Veronique R, Stinson, Kelly W, Zhang, Xiaoyan, Liu, Yongge, Hafkin, Jeffrey

“…OPC-167832, an inhibitor of decaprenylphosphoryl-β-d-ribose 2'-oxidase, demonstrated potent antituberculosis activity and a favorable safety profile in…”
Get full text

Fourteen-Day Bactericidal Activity, Safety, and Pharmacokinetics of Linezolid in Adults with Drug-Sensitive Pulmonary Tuberculosis by Diacon, Andreas H, De Jager, Veronique R, Dawson, Rodney, Narunsky, Kim, Vanker, Naadira, Burger, Divan A, Everitt, Daniel, Pappas, Frances, Nedelman, Jerry, Mendel, Carl M

“…Linezolid is increasingly used for the treatment of tuberculosis resistant to first-line agents, but the most effective dosing strategy is yet unknown. From…”
Get full text

Pretomanid Pharmacokinetics in the Presence of Rifamycins: Interim Results from a Randomized Trial among Patients with Tuberculosis by Ignatius, Elisa H, Abdelwahab, Mahmoud Tareq, Hendricks, Bronwyn, Gupte, Nikhil, Narunsky, Kim, Wiesner, Lubbe, Barnes, Grace, Dawson, Rodney, Dooley, Kelly E, Denti, Paolo

“…Shorter, more potent regimens are needed for tuberculosis. The nitroimidazole pretomanid was recently approved for extensively drug-resistant tuberculosis in…”
Get full text

Resistance to Mycobacterium tuberculosis Infection Among Household Contacts: A Multinational Study by Baliashvili, Davit, Gandhi, Neel R, Kim, Soyeon, Hughes, Michael, Mave, Vidya, Mendoza-Ticona, Alberto, Gonzales, Pedro, Narunsky, Kim, Selvamuthu, Poongulali, Badal-Faesen, Sharlaa, Upton, Caryn, Naini, Linda, Smith, Elizabeth, Gupta, Amita, Churchyard, Gavin, Swindells, Susan, Hesseling, Anneke, Shah, N Sarita

“…Some contacts of patients with tuberculosis remain negative on tests for tuberculosis infection, despite prolonged exposure, suggesting they might be resistant…”
Get full text

Drug interaction potential of high-dose rifampicin in patients with pulmonary tuberculosis by Stemkens, Ralf, Jager, Veronique de, Dawson, Rodney, Diacon, Andreas H., Narunsky, Kim, Padayachee, Sherman D., Boeree, Martin J., van Beek, Stijn W., Colbers, Angela, Coenen, Marieke J. H., Svensson, Elin M., Fuhr, Uwe, Phillips, Patrick P. J., te Brake, Lindsey H. M., Aarnoutse, Rob E.

“…ABSTRACT Accumulating evidence supports the use of higher doses of rifampicin for tuberculosis (TB) treatment. Rifampicin is a potent inducer of metabolic…”
Get full text

High Prevalence of Tuberculosis Infection and Disease in Child Household Contacts of Adults With Rifampin-resistant Tuberculosis by Kim, Soyeon, Wu, Xingye, Hughes, Michael D., Upton, Caryn, Narunsky, Kim, Mendoza-Ticona, Alberto, Khajenoori, Saltnat, Gonzales, Pedro, Badal-Faesen, Sharlaa, Shenje, Justin, Omoz-Oarhe, Ayotunde, Rouzier, Vanessa, Garcia-Prats, Anthony J., Demers, Anne-Marie, Naini, Linda, Smith, Elizabeth, Churchyard, Gavin, Swindells, Susan, Shah, N. Sarita, Gupta, Amita, Hesseling, Anneke C.

“…Household contact (HHC) investigation is an important strategy to identify individuals with tuberculosis (TB) exposure, infection and disease, including those…”
Get full text

Reply to Kim et al., "Optimal Dose or Optimal Exposure? Consideration for Linezolid in Tuberculosis Treatment" by Diacon, Andreas H, De Jager, Veronique R, Dawson, Rodney, Narunsky, Kim, Vanker, Naadira, Burger, Divan A, Everitt, Daniel, Pappas, Frances, Nedelman, Jerry, Mendel, Carl M

Get full text

High Prevalence of Tuberculosis Infection and Disease in Child Household Contacts of Adults With Rifampin-resistant Tuberculosis by Kim, Soyeon, Wu, Xingye, Hughes, Michael D., Upton, Caryn, Narunsky, Kim, Mendoza-Ticona, Alberto, Khajenoori, Saltnat, Gonzales, Pedro, Badal-Faesen, Sharlaa, Shenje, Justin, Omoz-Oarhe, Ayotunde, Rouzier, Vanessa, Garcia-Prats, Anthony J., Demers, Anne-Marie, Naini, Linda, Smith, Elizabeth, Churchyard, Gavin, Swindells, Susan, Shah, N. Sarita, Gupta, Amita, Hesseling, Anneke C.

Get full text

Increased bactericidal activity but dose-limiting intolerability at 50 mg·kg -1 rifampicin by Te Brake, Lindsey H M, de Jager, Veronique, Narunsky, Kim, Vanker, Naadira, Svensson, Elin M, Phillips, Patrick P J, Gillespie, Stephen H, Heinrich, Norbert, Hoelscher, Michael, Dawson, Rodney, Diacon, Andreas H, Aarnoutse, Rob E, Boeree, Martin J

“…Accumulating data have indicated that higher rifampicin doses are more effective and shorten tuberculosis treatment duration. This study evaluated the safety,…”
Get full text

Early phase evaluation of SQ109 alone and in combination with rifampicin in pulmonary TB patients by Heinrich, Norbert, Dawson, Rodney, du Bois, Jeannine, Narunsky, Kim, Horwith, Gary, Phipps, Andrew J, Nacy, Carol A, Aarnoutse, Rob E, Boeree, Martin J, Gillespie, Stephen H, Venter, Amour, Henne, Sonja, Rachow, Andrea, Phillips, Patrick P J, Hoelscher, Michael, Diacon, Andreas H

“…SQ109, an asymmetrical diamine, is a novel anti-TB drug candidate. This first study in patients was done to determine safety, tolerability, pharmacokinetics…”
Get full text

Protein binding of rifampicin is not saturated when using high-dose rifampicin by Litjens, Carlijn H C, Aarnoutse, Rob E, van Ewijk-Beneken Kolmer, Eleonora W J, Svensson, Elin M, Colbers, Angela, Burger, David M, Boeree, Martin J, te Brake, Lindsey H M

“…Abstract Background Higher doses of rifampicin are being investigated as a means to optimize response to this pivotal TB drug. It is unknown whether high-dose…”
Get full text

Central monitoring in a randomized, open-label, controlled phase 3 clinical trial for a treatment-shortening regimen for pulmonary tuberculosis by Bryant, Kia E., Yuan, Yan, Engle, Melissa, Kurbatova, Ekaterina V., Allen-Blige, Cynthia, Batra, Kumar, Brown, Nicole E., Chiu, Kuo wei, Davis, Howard, Elskamp, Mascha, Fagley, Melissa, Fedrick, Pamela, Hedges, Kimberley N.C., Narunsky, Kim, Nassali, Joanita, Phan, Mimi, Phan, Ha, Purfield, Anne E., Ricaldi, Jessica N., Robergeau-Hunt, Kathleen, Whitworth, William C., Sizemore, Erin E.

“…With the growing use of online study management systems and rapid availability of data, timely data review and quality assessments are necessary to ensure…”
Get full text

Effect of seven anti-tuberculosis treatment regimens on sputum microbiome: a retrospective analysis of the HIGHRIF study 2 and PanACEA MAMS-TB clinical trials by Musisi, Emmanuel, Wyness, Adam, Eldirdiri, Sahar, Dombay, Evelin, Mtafya, Bariki, Ntinginya, Nyanda E, Heinrich, Norbert, Kibiki, Gibson S, Hoelscher, Michael, Boeree, Martin, Aarnoutse, Rob, Gillespie, Stephen H, Sabiiti, Wilber, Musisi, Emmanuel, Mtafya, Bariki, Ntinginya, Nyanda E., Heinrich, Norbert, Kibiki, Gibson S., Hoelscher, Michael, Boeree, Martin, Gillespie, Stephen, Sabiiti, Wilber, Sloan, Derek, Hoffmann, Larissa, Noreña, Ivan, Lutchmun, Wandini, Dreisbach, Julia, Demel, Petra Gross, Kelly, Andrea, Brake, Lindsey te, Svensson, Elin, Aarnoutse, Rob, Honeyborne, Isobella, Wildner, Leticia Muraro, Hunt, Robert, McHugh, Timothy D., Nunn, Andrew J, Phillips, Patrick P.J., Gong, Xue, Dawson, Rodney, Narunsky, Kim, Diacon, Andreas, de Jager, Veronique, Friedrich, Sven, Sanne, Ian, Rassool, Mohammed, Mangu, Chacha, Manyama, Christina, Sabi, Issa, Minja, Lilian T., Mhimbira, Francis, Mbeya, Benno, Sasamalo, Mohamed, Reither, Klaus, Jugheli, Levan, Sam, Noel, Semvua, Hadija, Mpagama, Stellah, Liyoyo, Alphonce, Mmbaga, Blandina T., Adegbite, Bayode Romeo, Adegnika, Ayola Akim, Grobusch, Martin Peter, Grobusch, Martin P., Kirenga, Bruce, Ssengooba, Willy, Joloba, Moses, Khosa, Celso, Massango, Isabel, Azam, Khalide, Jani, Ilesh, Nliwasa, Mariott, Twabi, Hussein Hassan, Mukoka, Madalo, Msefula, Chisomo L.

“…Respiratory tract microbiota has been described as the gatekeeper for respiratory health. We aimed to assess the impact of standard-of-care and experimental…”
Get full text